secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001558370-24-013103
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences highlights best-in-class orexin-2 agonist, $3B revenue goal at Investor Day
--------------------------------------------------------------------------------

- BP1.15205 orexin-2 agonist shows highest potency vs. all publicly disclosed competitors, potential best-in-class.
- Pitolisant in IH: mean ESS improvement ~9 points beyond 1 year; majority achieve normal wakefulness; sNDA on track Q4 2024.
- Pitolisant-HD safety data up to 5x highest WAKIX dose; target PDUFA 2028; market research anticipates high uptake.
- Fragile X (ZYN-002): 40% median improvement in social avoidance (p=0.027) in methylated patients; Phase 3 topline mid-2025.
- EPX-100 in Dravet syndrome shows favorable safety vs approved drugs; topline 2026; Phase 3 LGS starts 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024013103/0001558370-24-013103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024013103/hrmy-20241001x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer